Alex Galbraith - November 17, 2023 The first CRISPR treatment – Casgevy wins UK approval for sickle cell disease In a world first, the UK medicines regulator has given the green light to a therapy employing ...
Alex Galbraith - September 1, 2023 Gene therapy – the status quo and future trends The uptick in recent approvals in the gene therapy space is emblematic of a field which is now ...
Rebecca Tollervey - May 9, 2023 Patenting antibodies – the latest developments from the EPO Boards of Appeal: Part 2 – inventive step We have conducted a review of Board of Appeal decisions relating to antibody patents published ...
Rebecca Tollervey - February 1, 2023 Patenting antibodies – the latest developments from the EPO Boards of Appeal The prosecution of patent applications relating to antibodies involves particular considerations. ...
Alex Galbraith - December 1, 2022 Antibody therapy for pets – following the human lead Over recent decades monoclonal antibody (mAb) therapy has developed from a standing start to become ...
Matthew Naylor - September 23, 2022 UPC: Rules of Procedure finalised and in force The Unitary Patent Court now has a revised set of Rules of Procedure. These came into force on 1 ...
Joseph Morgan - October 14, 2021 CRISPR - the future of gene editing In this Forward: On Demand vlog, Joseph Morgan and Alex Galbraith explore what CRISPR/Cas9 is, how ...
Alex Galbraith - May 12, 2021 Diagnosing concussion: liquid biopsy is changing the game Rugby, along with many other contact sports such as football, boxing and American football, has ...
Alex Galbraith - March 8, 2021 Detecting progress: liquid biopsy in lung cancer Lung cancer remained the leading cause of cancer death in 2020 with an estimated 1.8 million deaths ...